List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Microcapillary Quartz Sensors for Screening Injectability of High Concentration Protein Formulations

    SBC: Qatch Technologies, LLC            Topic: None

    The objective of this SBIR Phase I proposal is to determine the feasibility of viscosity characterization of high concentration protein formulations (HCF) by QATCH’s microcapillary quartz technology. HCFs are non-Newtonian fluids with shear-thinning behavior and they are administered to patients by subcutaneous or muscular injections. The injectability of HCFs depends on the viscosity at high-sh ...

    SBIR Phase I 2019 Department of CommerceNational Institute of Standards and Technology
  2. Topic 368: Biotherapy of Brain Tumors by Radioiodinated SapC-DOPS Nanovesicles

    SBC: Molecular Targeting Technologies, Inc.            Topic: NCI

    There is an urgent need for more effective drug delivery agents for treatment of brain tumors, which are among the most aggressive and intractable cancers. SapC-DOPS, a nanovesicle composed of saposin C (SapC) coupled to dioleoylphosphatidylserine (DOPS), has proven tumor targeting properties, which include crossing the blood-brain tumor barrier and binding the lipid tumor marker, extracellular ph ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Topic 377: Enabling Clinical Decision Support for Guideline Based Cancer Symptom Management

    SBC: KLESIS, LLC            Topic: NCI

    The objective of this proposal is to develop an electronic, rule-based clinical decision support system (CDS-Sx) that leverages national clinical practice guidelines (CPGs) to improve cancer symptom management. Specific tasks that will be performed include: 1) create software-ready computable algorithms for managing cancer-related fatigue and constipation that have been vetted with diverse cancer ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Topic 372: Development and Validation of Canine scFvs for Pre-Clinical Development of Targeted Therapeutics- Moonshot

    SBC: Vetigenics LLC            Topic: NCI

    The goal of this SBIR is to provide proof-of-concept of Vetigenics' canine-derived scFv phage display platform for rapid, cost effective production of highly versatile, canine-derived scFvs. scFvs against CD19, CD3 and CTLA4, three high-value, immunological molecules being targeted by antibody-based strategies in human cancer immunotherapy, will be isolated. Selected scFvs will be sequenced and bi ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Topic 373: Monoclonal Antibodies to RNA-modifications

    SBC: Abzyme Therapeutics, LLC            Topic: NCI

    Post-transcriptional RNA modification is quite complex as there are more than sixty known RNA modifications that occur in thousands of RNAs in eukaryotic cells. A number of these RNA modifications have been shown to influence the development and physiology of the central nervous system (CNS) and to be involved in carcinogenesis. Despite the growing interest in and importance of RNA modifications, ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Topic 373: Novel Mass Spectrometry Methods and Research Tools to Map Nucleotide Modifications in Cytosolic Transfer RNAs from Cancer Cells

    SBC: Ribonova Inc.            Topic: NCI

    Chemical modifications play a crucial role in the regulation of biological processes. Protein function is often modulated by tagging with phosphates, sugars, or lipids, while epigenomic marks on DNA or histones can regulate gene expression up or down. One area that lags behind is the mechanistic understanding of the role of RNA chemical modifications, sometimes referred to as the 'epitranscriptome ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Topic 374: Targeted and Sustained Release Microparticles for Colon Cancer Chemoprevention

    SBC: Zymeron Corporation            Topic: NCI

    Colorectal Cancer (CRC) is the third most common cancer both in men and women, as well as the second leading cause of cancer deaths with an estimated 135,430 new cases diagnosed and 50,260 deaths for 2017 in the United States. Given the limitations of screening tests and poor prognosis associated with advanced stage colorectal cancer, it would be of great interest in exploring chemoprevention stra ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Creation of an Accurate Model of the Topical Structure of PubMed and associated indicators

    SBC: SCITECH STRATEGIES, INC            Topic: NIDA

    NIH through NIDA seeks development of an advanced and sophisticated analytical tool and approaches to enhance the professional evaluation and decision support in life sciences management and administrationIn this Phase II project the Contractor will continue to develop indicators of impactful science and of how virtuous the research ise gtransparencyreproducibility and potential for translation ap ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. The objective of this contract is to develop an HIV latent reservoir assay using a microwell array consumable.

    SBC: Cell Microsystems, Inc.            Topic: NIAID

    A critical remaining challenge toward a true cure for HIV is understanding how latently infected cells evade the immune system and persist as lifelong viral reservoirsOne eradication strategythe so calledshock and killapproachrelies on cell activating compounds to reverse latent infectionand subsequent antiretroviral therapy to eradicate newly activated cellsHoweverthese compounds activate only a ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. The objective of this contract is to determine the feasibility of a clofazimine inhalation formulation for preclinical development in tuberculosis

    SBC: QrumPharma, Inc.            Topic: NIAID

    Multi drug resistant tuberculosisMDR TBis now estimated to be responsible fornew infections annuallyObservational studies have demonstrated the addition of clofazimine to MDR TB treatment regimens is an effective therapeutic strategy for clearing infections and improving patient outcomesHowevercurrent treatment regimens are longand prolonged systemic administration of clofazimine causes severe sid ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government